{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal XCEL-MT-OSTEO-ALPHA",
            "NStudiesAvail": 430108,
            "NStudiesFound": 3,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 3,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [
                              "Fernando Granell, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 5, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Hounsfield units quantification by tomography in both treatment arms"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Efficacy assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures by imaging procedures"
                        ],
                        "NCTId": [
                              "NCT02230514"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [
                              "M\u00e0rius Aguirre, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 11, 2018"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety will be assessed by collecting adverse events throughout the experimental phase, which includes a follow-up of 12 months",
                              "Feasibility will be measured by assessing the percentage of patients to which bone marrow puncture is made are thereafter treated and by checking the cascade of procedures to confirm the global process is viable."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head",
                              "Feasibility of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head"
                        ],
                        "NCTId": [
                              "NCT01605383"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OverallOfficialName": [
                              "Joan Bag\u00f3, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 3, 2018"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety will be assessed by collecting adverse events throughout the experimental phase, which includes a follow-up of 12 months",
                              "Feasibility will be measured by assessing the percentage of patients to which bone marrow puncture is made are thereafter treated and by checking the cascade of procedures to confirm the global process is viable."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "safety of XCEL-MT-OSTEO-ALPHA (tissue engineering product composed by \"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)",
                              "Feasibility of XCEL-MT-OSTEO-ALPHA (composed by \"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)"
                        ],
                        "NCTId": [
                              "NCT01552707"
                        ]
                  }
            ]
      }
}